Your browser doesn't support javascript.
loading
Beyond insurance status: the impact of Medicaid expansion on the diagnosis of Hepatocellular Carcinoma.
Papageorge, Marianna V; Woods, Alison P; de Geus, Susanna W L; Ng, Sing Chau; Paasche-Orlow, Michael K; Segev, Dorry; McAneny, David; Kenzik, Kelly M; Sachs, Teviah E; Tseng, Jennifer F.
Afiliação
  • Papageorge MV; Department of Surgery, Boston Medical Center, Boston University School of Medicine, Boston, MA, USA.
  • Woods AP; Department of Surgery, Boston Medical Center, Boston University School of Medicine, Boston, MA, USA; Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • de Geus SWL; Department of Surgery, Boston Medical Center, Boston University School of Medicine, Boston, MA, USA.
  • Ng SC; Department of Surgery, Boston Medical Center, Boston University School of Medicine, Boston, MA, USA.
  • Paasche-Orlow MK; Department of Medicine, Boston Medical Center, Boston University School of Medicine, Boston, MA, USA.
  • Segev D; Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • McAneny D; Department of Surgery, Boston Medical Center, Boston University School of Medicine, Boston, MA, USA.
  • Kenzik KM; Department of Surgery, Boston Medical Center, Boston University School of Medicine, Boston, MA, USA; Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
  • Sachs TE; Department of Surgery, Boston Medical Center, Boston University School of Medicine, Boston, MA, USA.
  • Tseng JF; Department of Surgery, Boston Medical Center, Boston University School of Medicine, Boston, MA, USA. Electronic address: Jennifer.Tseng@BMC.org.
HPB (Oxford) ; 24(8): 1271-1279, 2022 08.
Article em En | MEDLINE | ID: mdl-35042672
ABSTRACT

BACKGROUND:

Medicaid expansion has led to earlier stage diagnoses in several cancers but has not been studied in hepatocellular carcinoma (HCC), a disease with complex risk factors. We examined the effect of Medicaid expansion on the diagnosis of HCC and associations with county-level social vulnerability.

METHODS:

Patients with HCC <65 years of age were identified from the SEER database (2010-2016). County-level social vulnerability factors were obtained from the CDC SVI and BRFSS. A Difference-in-Difference analysis evaluated change in early-stage diagnoses (stage I-II) between expansion and non-expansion states. A Difference-in-Difference-in-Difference analysis evaluated expansion impact among counties with higher proportions of social vulnerability.

RESULTS:

Of 19,751 patients identified, 81.5% were in expansion states. Uninsured status decreased in expansion states (6.3%-2.4%, p < 0.0001) and remained unchanged in non-expansion states (12.7%-14.8%, p = 0.43). There was no significant difference in the incidence of early-stage diagnoses between expansion states and non-expansion states. Results were consistent when accounting for social vulnerability.

CONCLUSION:

Medicaid expansion was not associated with earlier stage diagnoses in patients with HCC, including those with higher social vulnerability. Unlike other cancers, expanded access did not translate into higher utilization of care in HCC, suggesting barriers on a multitude of levels.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Neoplasias Hepáticas Tipo de estudo: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Limite: Humans País/Região como assunto: America do norte Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Neoplasias Hepáticas Tipo de estudo: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Limite: Humans País/Região como assunto: America do norte Idioma: En Ano de publicação: 2022 Tipo de documento: Article